CXCL12 and neoplasm: Preclinical studies show that CTCE-9908, another CXCR4 inhibitor, competitively inhibits the interaction between the CXCR4 receptor and its ligand SDF-1α, which blocks the function of CXCR4, thus suppressing tumor growth and metastasis [46].